Vancouver, British Columbia, Canada – TheNewswire - July 2, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce that it has filed its audited annual consolidated financial statements for the financial year ended December 31, 2024 (the “2024 Year End Financial Statements”). The 2024 Year End Financial Statements, together with detailed information regarding the Company's financial results...Read more
Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550 patients1 Strengthened commercial preparations and manufacturing capabilities through partnerships with Osmind and Thermo Fisher Scientific, respectively APPROACH expects to...Read more
HALIFAX, NS / ACCESS Newswire / June 30, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2025. Corporate update In Q3 FY2025, MedMira launched its recently Health Canada approved Multiplo® Rapid TP/HIV Test (Multiplo® TP/HIV) and its latest generation of its Reveal® Rapid HIV Test in Canada through its partner Trimedic. In addition, the Company continued its regulatory...Read more
REDWOOD CITY, Calif. / Jun 27, 2025 / Business Wire / Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the fiscal quarter ended March 31, 2025. First Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $10.4 million as of March 31, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were...Read more
Third quarter financial results Third quarter loss per share1 was $0.20 compared to earnings per share of $0.40 in the year-ago quarter. The decline in earnings per share was primarily driven by prior year after-tax gains related to fair value adjustments on variable prepaid forward derivatives and a partial sale of the Company's equity method investment in Cencora, and higher tax expense in the current quarter. Adjusted earnings per...Read more
Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA® at medical conferences and a planned KOL event MDNA11 continues to exhibit compelling deep and durable anti-tumor activity in difficult-to-treat solid tumors with best-in-class potential relative to competing IL-2 programs Results...Read more
Third quarter revenues increased 36% compared to 3Q24 Third quarter net loss of $0.032 per share QUÉBEC CITY / Jun 26, 2025 / Business Wire / Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), today announced financial results for its third quarter ended on April 30, 2025. Management Comments “The operating cash flows generated by Altius revenues continued to support the development progress of...Read more
Three Patients Treated in Hemopurifier® Cancer Trial; Indian Regulatory Approval Achieved; Operating Expenses Reduced; R&D Advances Support Expanded Indications Including Long COVID Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 26, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening...Read more
Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $20.2 million US commercial launch of GRAFAPEX™ executed in February 2025, following swiftly on the FDA's approval in January 2025, with initial indicators supporting Medexus's confidence in the product's potential Management to host conference call at 8:00 AM Eastern time on Thursday, June...Read more
LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing Five U.S. government proposals submitted, totalling up to US$125 million HALIFAX, Nova Scotia, June 25, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures,...Read more
Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for Submission to FDA in First Half of Calendar 2025 NDA to be Supported by Data from Phase 3 STRIVE-ON Safety Trial, which Met Primary Endpoint and Provided Evidence of Clinical Benefit Compared to Orally Administered Nimodipine Secured Private...Read more
Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of this year PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Company showcases promising clinical-stage pipeline of five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders SOUTH SAN FRANCISCO, Calif. / Jun 17, 2025 / Business Wire...Read more
Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and introducing revenue guidance of $12-$16 million for the full fiscal year 2026 Submitted PMA supplement for second-generation LungFit® PH to FDA International distribution partnerships now provide access to markets representing over 2...Read more
Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024 Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024 EBITDA loss improved 59% in Q4 2025 compared to Q4 2024, and 17% in FY 2025 compared to FY 2024 BOULDER, CO / ACCESS Newswire / June 17, 2025 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and...Read more
Singapore, Singapore--(Newsfile Corp. - June 16, 2025) - Mobile-health Network Solutions (Nasdaq: MNDR) ("MNDR" or "the Company"), a leading MedTech innovator ranked among Asia-Pacific's high-growth companies, today announced financial results for the first six months of its fiscal year 2025 ("H1 FY2025"). H1 FY2025 performance: Short-term impact from transition to leaner, stronger model For the period ended December 31, 2024, the...Read more
ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced financial results for the fiscal first quarter of 2025 which ended April 30, 2025. Fiscal First Quarter Financial Results Total revenue for the first...Read more
FARMINGDALE, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2025. Financial Highlights The Company’s third-quarter revenue of $6.4 million declined by $1.6 million or 20% compared to the same period in the prior year across all geographic areas. This is due to general continued headwinds in the life...Read more
Revenue grew 336.5% to $14.4 million from prior year (excluding ACT Genomics) Raises full year revenue outlook to $80 - $100 million (excluding ACT Genomics) IM8 contributed $5.7 million in Q1, with $2.8 million in March alone & provides Q2 revenue projections IM8 has more than 55,000 customers with 4.9 million servings delivered and counting Details of crypto strategy and Bitcoin adoption to be announced soon as part of...Read more
Updates fiscal 2025 revenue guidance range Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET RESEARCH TRIANGLE PARK, N.C. / Jun 11, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the...Read more
GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2025. Recent Business Updates Therapy Selection and MRD Personalized Minimal Residual Disease (MRD) product,...Read more
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE